Integra LifeSciences (IART) Jefferies Global Healthcare Conference 2026 summary

Business overview and growth drivers

• Operates in neurosurgery and regenerative medicine with two divisions: Specialty Surgery and Tissue Reconstruction.

• Specialty Surgery targets a $6B market, holding top share positions in neurosurgery and instrumentation.

• Tissue Reconstruction addresses a $2.5B market, leading in tissue reconstruction and offering biologics and synthetics for complex wounds.

• 90% of business is inpatient, with strong recurring demand and clinical evidence supporting products.

• Relaunch of SurgiMend expected to accelerate growth and regain market share.

Leadership and strategic direction

• Stuart Essig returned as CEO and Chairman effective May 1, bringing deep company knowledge.

• No changes to ongoing transformation; focus remains on operational initiatives and execution.

• Emphasis shifting from remediation to commercial readiness and customer engagement.

• Execution is the top priority for the next several quarters.

Operational transformation and compliance

• Launched a Compliance Master Plan in 2024 to strengthen quality management across 17 sites.

• Centralized quality and supply chain efforts to improve efficiency and planning.

• Most remediation activities to be completed by year-end, with improved supply chain visibility already evident.

• Transformation is ongoing but showing positive early results.